Loading stock data…
XOMAO
$25.23+0.04 (+0.16%)
Market ClosedLast close May 1
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
XOMA Royalty Corporation in the Healthcare sector is trading at $25.23. The stock is currently 4% below its 52-week high of $26.40, remaining 2.7% above its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why XOMAO maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$25.23
Potential Upside
0.2%
Whystock Fair Value$25.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.49
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Strong income play. Yield provides a meaningful total return floor.
820.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.78%
Volume
Today's trading volume
8,316
Recent News
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped.
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
After announcing healthy earnings, XOMA Royalty Corporation's ( NASDAQ:XOMA ) stock rose over the last week. While the...
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses
Key Insights Given the large stake in the stock by institutions, XOMA Royalty's stock price might be vulnerable to...